The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma

Nagata, 1997, Apoptosis by death factor, Cell, 88, 355, 10.1016/S0092-8674(00)81874-7 Vaux, 1994, An evolutionary perspective on apoptosis, Cell, 76, 777, 10.1016/0092-8674(94)90350-6 Ambrosini, 1997, A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma, Nat Med, 3, 917, 10.1038/nm0897-917 Tamm, 1998, IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, Caspase, anticancer drugs, Cancer Res, 58, 5315 Li, 1999, Pleiotropic cell-division defects and apoptosis induced by interference with survivin function, Nat Cell Biol, 1, 461, 10.1038/70242 Sandler, 1999, Survivin in apoptosis and solid tumors of childhood, Surg Forum, 50, 571 Evans, 1971, A proposed staging for children with neuroblastoma. Children's Cancer Study Group A, Cancer, 27, 374, 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G Shapiro, 1993, Detection of N-myc gene amplification by fluorescence in situ hybridization: Diagnostic utility for neuroblastoma, Am J Pathol, 142, 1339 Takamizawa, 2001, The Survivin: Fas ratio in pediatric renal tumors, J Pediatr Surg, 36, 37, 10.1053/jpsu.2001.20000 Walczak, 1997, TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL, Embo J, 16, 5386, 10.1093/emboj/16.17.5386 Pan, 1997, The receptor for the cytotoxic ligand TRAIL, Science, 276, 111, 10.1126/science.276.5309.111 Pan, 1997, An antagonist decoy receptor and a death domain-containing receptor for TRAIL, Science, 277, 815, 10.1126/science.277.5327.815 Sheridan, 1997, Control of TRAIL induced apoptosis by family of signaling and decoy receptors, Science, 277, 818, 10.1126/science.277.5327.818 Marsters, 1997, A novel receptor for Apo2L/TRAIL contains a truncated death domain, Curr Biol, 7, 1003, 10.1016/S0960-9822(06)00422-2 Thompson, 1995, Apoptosis in the pathogenesis and treatment of disease, Science, 267, 1456, 10.1126/science.7878464 Yang, 1996, Molecular thanatopsis: A discourse on the BCL2 family and cell death, Blood, 88, 386, 10.1182/blood.V88.2.386.bloodjournal882386 LaCasse, 1998, The inhibitors of apoptosis (IAPs) and their emerging role in cancer, Oncogene, 17, 3247, 10.1038/sj.onc.1202569 Lu, 1998, Expression of a novel apoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas, Cancer Res, 58, 1808 Kawasaki, 1998, Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer, Cancer Res, 58, 5071 Swana, 1999, Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer, N Engl J Med, 341, 452, 10.1056/NEJM199908053410614 Adida, 1998, Anti-apoptosis gene, survivin, and prognosis of neuroblastoma, Lancet, 351, 882, 10.1016/S0140-6736(05)70294-4 Islam, 2000, High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma, Oncogene, 19, 617, 10.1038/sj.onc.1203358 Islam, 2000, Role of Survivin, Whose gene is mapped to 17q25, in human neuroblastoma and identification of a novel dominant-negative isoform, survivin-β/2B, Med Pediatr Oncol, 35, 550, 10.1002/1096-911X(20001201)35:6<550::AID-MPO12>3.0.CO;2-Y Brodeur, 1984, Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage, Science, 224, 1121, 10.1126/science.6719137 Seeger, 1985, Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastoma, N Engl J Med, 313, 1111, 10.1056/NEJM198510313131802 Schwab, 1984, Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma, Proc Natl Acad Sci U S A, 81, 4940, 10.1073/pnas.81.15.4940